Active Ingredient History
Alteplase, sold under the brand name Activase among others, is a biosynthetic form of human tissue-type plasminogen activator (t-PA). It is a thrombolytic medication used to treat acute ischemic stroke, acute ST-elevation myocardial infarction, pulmonary embolism associated with low blood pressure, and blocked central venous catheter. It is given by injection into a vein or artery. Alteplase is the same as the normal human plasminogen activator produced in vascular endothelial cells and is synthesized via recombinant DNA technology in Chinese hamster ovary cells (CHO). Alteplase causes the breakdown of a clot by inducing fibrinolysis. Wikipedia
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Abdominal Abscess (Phase 3)
Abscess (Phase 2/Phase 3)
Accidents (Phase 2)
Angina Pectoris (Phase 3)
Arterial Occlusive Diseases (Phase 3)
Atherosclerosis (Phase 4)
Brain Infarction (Phase 2)
Brain Ischemia (Phase 3)
Bronchitis (Phase 2)
Cardiovascular Diseases (Phase 3)
Catheterization, Central Venous (Phase 2)
Catheter Obstruction (Phase 3)
Catheter-Related Infections (Phase 2)
Catheters (Phase 4)
Cerebral Arteries (Phase 2)
Cerebral Hemorrhage (Phase 3)
Cerebral Infarction (Phase 3)
Cerebral Intraventricular Hemorrhage (Phase 3)
Cerebrovascular Disorders (Phase 3)
Chemotherapy, Adjuvant (Phase 1)
Coronary Artery Disease (Phase 1)
Coronary Disease (Phase 3)
COVID-19 (Phase 2)
Drugs, Investigational (Phase 4)
Embolism (Phase 1)
Empyema (Phase 4)
Empyema, Pleural (Phase 4)
Eye Diseases (Phase 3)
Fibrinolysis (Phase 2)
Healthy Volunteers (Phase 2)
Heart Diseases (Phase 3)
Hematoma, Subdural (Phase 4)
Hemodialysis, Home (Phase 4)
Hemorrhage (Phase 4)
Hydrocephalus (Phase 1/Phase 2)
Hypertension (Phase 3)
Hypertension, Pulmonary (Phase 4)
Hypertrophy, Left Ventricular (Phase 4)
Infarction, Middle Cerebral Artery (Phase 4)
Infections (Phase 4)
Intestinal Diseases (Phase 2)
Intracranial Aneurysm (Phase 1/Phase 2)
Intracranial Hemorrhage, Hypertensive (Phase 2)
Intracranial Thrombosis (Phase 3)
Ischemic Stroke (Phase 4)
Lung Diseases (Phase 2)
Lung Neoplasms (Phase 2)
Macular Degeneration (Phase 2/Phase 3)
Muscle Weakness (Phase 2)
Myocardial Ischemia (Phase 3)
Neoplasm Metastasis (Phase 1)
Neoplasms (Phase 2)
Nervous System Diseases (Phase 2)
Percutaneous Coronary Intervention (Phase 4)
Peripheral Arterial Disease (Phase 2)
Peritoneal Dialysis (Phase 1)
Pleural Diseases (Phase 4)
Pleural Effusion (Phase 4)
Postphlebitic Syndrome (Phase 3)
Postthrombotic Syndrome (Phase 4)
Protein-Losing Enteropathies (Phase 2)
Radiation Pneumonitis (Phase 4)
Respiratory Distress Syndrome (Phase 3)
Respiratory Insufficiency (Phase 2)
Retinal Artery Occlusion (Phase 3)
Retinal Hemorrhage (Phase 2/Phase 3)
Retinal Vein Occlusion (Phase 1)
Sensation (Phase 2)
Severe Acute Respiratory Syndrome (Phase 2)
Short Bowel Syndrome (Phase 4)
Sinus Thrombosis, Intracranial (Phase 2/Phase 3)
Spinal Diseases (Phase 2)
ST Elevation Myocardial Infarction (Phase 4)
Stroke ()
Subarachnoid Hemorrhage (Phase 3)
Thrombectomy (Phase 4)
Thromboembolism (Phase 4)
Thrombolytic Therapy (Phase 4)
Thrombophilia (Phase 2)
Thrombophlebitis (Phase 1)
Thrombosis (Phase 4)
Tissue Plasminogen Activator (Phase 4)
Upper Extremity Deep Vein Thrombosis (Phase 2)
Vascular Access Devices (Phase 3)
Vasospasm, Intracranial (Phase 1/Phase 2)
Venous Thromboembolism (Phase 3)
Venous Thrombosis (Phase 4)
Ventricular Dysfunction, Right (Phase 4)
Wet Macular Degeneration (Phase 3)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
